Washington Code 69.51.040 – Controlled substances therapeutic research program
Current as of: 2023 | Check for updates
|
Other versions
(1) There is established in the commission the controlled substances therapeutic research program. The program shall be administered by the department. The commission shall promulgate rules necessary for the proper administration of the Controlled Substances Therapeutic Research Act. In such promulgation, the commission shall take into consideration those pertinent rules promulgated by the United States drug enforcement agency, the food and drug administration, and the national institute on drug abuse.
Terms Used In Washington Code 69.51.040
- Commission: means the pharmacy quality assurance commission;
Washington Code 69.51.030Department: means the department of health; and
Washington Code 69.51.030Practitioner: means a physician licensed pursuant to chapter 18. See Washington Code 69.51.030
(2) Except as provided in RCW 69.51.050(4), the controlled substances therapeutic research program shall be limited to cancer chemotherapy and radiology patients and glaucoma patients, who are certified to the patient qualification review committee by a practitioner as being involved in a life-threatening or sense-threatening situation. No patient may be admitted to the controlled substances therapeutic research program without full disclosure by the practitioner of the experimental nature of this program and of the possible risks and side effects of the proposed treatment in accordance with the informed consent provisions of chapter 7.70 RCW.
(3) The commission shall provide by rule for a program of registration with the department of bona fide controlled substance therapeutic research projects.